Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Genmab A/S (GNMSF)

Genmab A/S (GNMSF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Genmab A/S CARL JACOBSENS VEJ 30 VALBY G7 2500 DNK

www.genmab.com Employees: 2,682 P: 45-7020-2728

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.

Key Statistics

Overview:

Market Capitalization, $K 21,087,536
Enterprise Value, $K 19,658,126
Shares Outstanding, K 66,075
Annual Sales, $ 3,121 M
Annual Net Income, $ 1,137 M
Last Quarter Sales, $ 1,022 M
Last Quarter Net Income, $ 401,000 K
EBIT, $ 1,316 M
EBITDA, $ 1,376 M
60-Month Beta 0.88
% of Insider Shareholders 1.54%
% of Institutional Shareholders 0.00%
Float, K 65,057
% Float 98.46%
Short Interest 93
Short Float 0.14%
Short Volume Ratio 1.00

Growth:

1-Year Return 58.78%
3-Year Return -27.28%
5-Year Return -19.44%
5-Year Revenue Growth 288.04%
5-Year Earnings Growth 186.27%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 6.46 on 11/06/25
Next Earnings Date 02/11/26
Earnings Per Share ttm 20.63
EPS Growth vs. Prev Qtr 19.19%
EPS Growth vs. Prev Year 121.23%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

GNMSF Ratios

Ratio
Price/Earnings ttm 15.36
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 23.98%
Return-on-Assets % 19.45%
Profit Margin % 36.44%
Debt/Equity 0.00
Price/Sales 6.71
Price/Cash Flow 20.87
Price/Book 3.64
Book Value/Share 87.03
Interest Coverage 5.64
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar